Authors
Huan Gao, Sha Liao, Yujiao Gao, Yusi Shen, Hu Hao, Can Zhou, Heng Liao
Published in
Cytotechnology. Volume 78. Issue 6. Pages 225. Epub Oct 30, 2026.
Abstract
Inflammatory responses play a pivotal role in cerebral ischemia/reperfusion (I/R) injury, with microglia‑driven neuroinflammation further exacerbating neuronal damage. Atractylenolide I (ATR-I), a natural bioactive compound derived from Atractylodes macrocephala, exhibits anti-inflammatory properties by modulating signaling cascades. Nevertheless, its potential neuroprotective effects against cerebral I/R injury require further investigation.This study examined ATR-I's impact on microglial involvement in I/R-induced injury using two models: (i) BV2 microglial cells subjected to OGD/R in vitro, and (ii) a murine model of MCAO/R in vivo. Assessments included cellular viability, apoptosis, and inflammatory mediator secretion in vitro, while infarct volume, neurological function, neuronal apoptosis, and microglial activation were evaluated in vivo. Molecular mechanisms were explored via western blot and immunofluorescence. ATR-I substantially enhanced cellular survival while reducing apoptotic cell death and suppressing inflammatory cytokines secretion in OGD/R-treated BV2 cells. On the mechanistic front, ATR-I blocked two key inflammatory pathways: NLRP3 inflammasome activation and the TLR4/NF-κB signaling cascade. In experiments using the MCAO/R model, ATR-I treatment reduced infarct extent, improved neurological recovery, decreased neuronal apoptosis, and suppressed microglial activation-effects mediated by suppressing the TLR4/NF-κB/NLRP3 pathway. The ability of ATR-I to counteract cerebral I/R injury arises from its suppressive effect on the TLR4/NF‑κB/NLRP3 cascade. On account of this effect, ATR-I is considered a promising therapeutic agent for acute cerebral ischemia therapy, given its capacity to modulate microglia‑mediated neuroinflammatory reactions.
The online version contains supplementary material available at https://doi.org/10.1007/s10616-026-01101-9.
PMID:
42966934
Bibliographic data and abstract were imported from PubMed on 01 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 32
- Comments 0